Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial - PubMed

ClinicalTrials.gov Identifier: NCT05433480.
pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov